| Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that the company is scheduled to participate in the following investor conferences in May and June: H.C. |
globenewswire.com |
2025-05-15 11:59:00 |
Czytaj oryginał (ang.) |
| After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) |
Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-05-08 14:35:46 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. |
globenewswire.com |
2025-05-01 20:15:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript |
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript |
seekingalpha.com |
2025-05-01 16:09:12 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates |
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.42 per share a year ago. |
zacks.com |
2025-05-01 13:20:44 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update |
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwinds Strategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026 Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J. |
globenewswire.com |
2025-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting |
FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present real-world data for its first-in-class treatment VOQUEZNA® (vonoprazan) at Digestive Disease Week® (DDW) being held May 3–6, 2025, in San Diego, CA. VOQUEZNA is the first and only treatment of its kind approved by the U.S. Food and Drug Administration for use in adults for the relief of heartburn associated with Non-Erosive GERD and for the treatment of all severities of Erosive Esophagitis (EE), commonly referred to as Erosive GERD, and relief of related heartburn. |
globenewswire.com |
2025-04-28 11:59:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 |
• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update. |
globenewswire.com |
2025-04-23 12:00:00 |
Czytaj oryginał (ang.) |
| Frazier Life Sciences Appoints Aditya Kohli to Partner |
PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ: HLVX, IPO in 2022), Phathom Pharmaceuticals (NASDAQ: PHAT, IPO in 2019), and Scout Bio (acquired by Ceva Santé Animale). He previously acted. |
businesswire.com |
2025-04-17 12:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors |
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. |
globenewswire.com |
2025-04-16 12:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference |
FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025, at 10:15 am ET. |
globenewswire.com |
2025-04-03 12:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Steven Basta as President and Chief Executive Officer, the Company's Board of Directors has approved the grant of inducement awards. |
globenewswire.com |
2025-04-01 20:15:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Announces Leadership Succession |
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds Terrie Curran, who is stepping down as President and CEO and as a member of the Board of Directors for personal reasons. |
globenewswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan) |
For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the new GERD IS NO JOKE campaign VOQUEZNA is a potassium competitive acid blocker (PCAB), the first and only FDA-approved treatment of its kind for both types of GERD 1 A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J. |
globenewswire.com |
2025-03-31 11:59:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript |
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham Annabel Samimy - Stifel Kristen Kluska - Cantor Fitzgerald Paul Choi - Goldman Sachs Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call. |
seekingalpha.com |
2025-03-06 14:13:23 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates |
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.80 per share a year ago. |
zacks.com |
2025-03-06 12:10:26 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business updates. |
globenewswire.com |
2025-03-06 10:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 |
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update. |
globenewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference |
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET. |
globenewswire.com |
2025-01-29 10:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets |
FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today it has submitted a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA). The petition formally requests correction of the Orange Book listings for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets to accurately reflect the full 10-year NCE exclusivity period until May 3, 2032. |
globenewswire.com |
2024-12-11 10:00:00 |
Czytaj oryginał (ang.) |
| Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround |
Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-12-06 12:35:18 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know |
Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-19 15:01:11 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript |
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial & Business Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Paul Choi - Goldman Sachs Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2024 Earnings Results Call. |
seekingalpha.com |
2024-11-10 05:54:12 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates |
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to loss of $0.76 per share a year ago. |
zacks.com |
2024-11-07 12:20:16 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December: |
globenewswire.com |
2024-11-04 10:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 |
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update. |
globenewswire.com |
2024-10-28 10:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting |
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, being held October 25-30 in Philadelphia, PA. VOQUEZNA is approved for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (Non-Erosive GERD), for the treatment of all severities of Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of related heartburn, and in combination with antibiotics for the eradication of Helicobacter pylori (H. pylori) infection.1 VOQUEZNA is the first and only U.S. Food and Drug Administration (FDA)-approved potassium-competitive acid blocker (PCAB).2 |
globenewswire.com |
2024-10-27 14:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) |
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty. |
prnewswire.com |
2024-09-25 23:15:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September: |
globenewswire.com |
2024-08-29 12:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants |
FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 shares of its common stock and pre-funded warrants to purchase 2,608,922 shares of common stock. The shares of common stock are being sold at a price of $11.50 per share and the pre-funded warrants are being sold at a price of $11.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $130 million. The offering is expected to close on or about August 20, 2024, subject to satisfaction of customary closing conditions. |
globenewswire.com |
2024-08-19 12:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript |
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CEO Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Paul Choi - Goldman Sachs Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to Phathom Pharmaceuticals Second Quarter 2024 Earnings Results Call. |
seekingalpha.com |
2024-08-10 18:52:09 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates |
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $0.84 per share a year ago. |
zacks.com |
2024-08-08 14:21:21 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update |
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter of 2024, and provided recent business updates. |
globenewswire.com |
2024-08-08 12:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults |
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA represents the first major innovation in GERD treatment in over 30 years and the only FDA-approved treatment of its kind available in the U.S. A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J. |
globenewswire.com |
2024-07-18 12:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays |
Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation. |
seekingalpha.com |
2024-06-26 10:11:34 |
Czytaj oryginał (ang.) |
| Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze |
One of the fastest ways to make money on the stock market is to gamble on short-term contrarian positions against the shorting interest of a stock. Since every company's proportion of shorted stock is publicly available, it's pretty easy to see which companies are expected to lose value. |
investorplace.com |
2024-06-07 10:17:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences |
FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in June: |
globenewswire.com |
2024-05-28 12:00:00 |
Czytaj oryginał (ang.) |
| Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript |
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q1 2024 Results Conference Call May 9, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial & Business Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham & Company Paul Choi - Goldman Sachs Annabel Samimy - Stifel Matthew Caufield - H.C. Wainright Operator Hello, and welcome to Phathom Pharmaceuticals First Quarter 2024 Earnings Results Call. |
seekingalpha.com |
2024-05-11 23:03:08 |
Czytaj oryginał (ang.) |
| The 3 Best Healthcare Stocks to Buy in May 2024 |
Healthcare is a basic human need that can withstand economic downturns. Indeed, this important endeavor receives a huge amount of funds in developed countries globally and the West in particular. |
investorplace.com |
2024-05-10 12:00:00 |
Czytaj oryginał (ang.) |